Prolonged use of linezolid in bone and joint infections: a retrospective analysis of adverse effects.

Karin VeermanJon GoosenKarin SpijkersNynke G L JagerPetra HeesterbeekDenise Telgt
Published in: The Journal of antimicrobial chemotherapy (2023)
Linezolid could be considered an alternative option to the current standard of IV glycopeptides for the treatment of bone and joint infection for up to 12 weeks. If patients pass the first 28 days of therapy, the likelihood of successful completion of therapy is high with a low risk of serious ADEs.